Deals Shaping the Medical Industry (02/1996)
Summarizing the deals in the medical industry.
You may also be interested in...
Some reimbursement agencies in Europe have been misinterpreting Translarna’s label and stopping access to the drug for boys with Duchenne muscular dystrophy who have been taking it but whose disease has progressed, PTC says.
PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.
Increased uptake for generics and biosimilars must become Belgium’s “new normal” in the wake of the coronavirus crisis, local off-patent industry association Medaxes has argued.